Hemogenyx Pharmaceuticals PLC Lease of New York Mink Building Custom Laboratory
18 Ottobre 2021 - 8:00AM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
18 October 2021
18 October 2021
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Lease of New York Mink Building Custom Laboratory
Hemogenyx Pharmaceuticals has signed a lease with The Janus
Property Company ("Janus") for a new custom-designed and built
laboratory in the Mink Building, located in the Manhattanville
Factory District of New York, adjacent to Columbia University and
City College.
The Company's new 10,000 rentable square feet lab will include
two clean rooms purpose-built by Janus, allowing it to pursue
commercialisation of its major cell therapy product candidates by
manufacturing cells in-house, starting with its HEMO-CAR-T cell
therapy for the treatment of acute myeloid leukemia.
The Mink Building, located on West 126th Street at Amsterdam
Avenue, has been completely re-built by Janus while preserving and
enhancing the building's singular industrial charms. The building
features expansive ceiling heights and flexible, technology-enabled
office and lab settings.
Dr Vladislav Sandler, Co-Founder and Chief Executive Officer,
Hemogenyx Pharmaceuticals, commented: "I am very excited to be on
the West Side of Manhattan in the historic Manhattanville Factory
District. Having toured every life sciences option in the New York
City area, the choice for our lab's continued growth was clear.
With several current and future vivarium options, the opportunity
to collaborate with nearby Columbia University and City College,
the convenient location for our staff, and Janus's commitment to
the life sciences industry and our company, the Mink Building
represents an unmatched combination of advantages. We will be
growing our staff and operations significantly over the next three
years, and this lab and building provide us everything we need.
Janus also provides us with the critical flexibility we need for
our future, by allowing us to grow out of this lab and into its
numerous other properties in the District without penalty."
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New
York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to treat blood and
autoimmune disease and to bring the curative power of bone marrow
transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary
product candidates, as well as platform technologies that it uses
as engines for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. The Company's technology
has the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
About The Janus Property Company
The Janus Property Company is a developer, long-term owner and
manager of commercial, mixed-use and residential properties in New
York City, with a current primary focus on the creative development
of the Manhattanville Factory District in West Harlem. Since 1989,
Janus has consistently undertaken important and complex civic
projects, creating enduring value for its tenants, partners,
lenders and the greater New York City community. It specializes in
understanding the numerous issues involved in developing and
managing real property in New York. This has resulted in an
impressive array of successful projects ranging from the extensive
rehabilitation and new construction of market rate and affordable
rental and condominium housing to mixed-use projects, small and
large-scale life science properties and master-planned neighborhood
development. Janus is headquartered in the Manhattanville Factory
District.
www.JanusProperty.com
www.TheFactoryDistrict.com
www.MaltHouseNYC.com
www.TaysteeBldg.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEASEKFDDFFFA
(END) Dow Jones Newswires
October 18, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Silver Falcon (LSE:SILF)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Silver Falcon (LSE:SILF)
Storico
Da Lug 2023 a Lug 2024